Title:
HETEROCYCLOALKYL-SUBSTITUTED POLYHETEROAZOLE DERIVATIVE AS MEDICAL DRUG FOR TREATMENT AND/OR PREVENTION OF RS VIRUS INFECTIOUS DISEASE
Document Type and Number:
WIPO Patent Application WO/2022/270628
Kind Code:
A1
Abstract:
The present invention provides a compound that is useful for treatment or prevention of RS virus infection. The present invention pertains to: a compound represented by formula (I): (where Y1, Y2, Y3, X4, etc., are as defined in the specification), an enantiomer thereof or a pharmaceutical salt thereof; a use of these compounds for treatment or prevention of RS virus infectious disease; and a pharmaceutical composition including these compounds.
Inventors:
MATSUOKA SHIGERU (JP)
TSUCHIKAWA HIROSHI (JP)
YAMADA KENTARO (JP)
KATO AKIRA (JP)
TSUCHIKAWA HIROSHI (JP)
YAMADA KENTARO (JP)
KATO AKIRA (JP)
Application Number:
PCT/JP2022/025361
Publication Date:
December 29, 2022
Filing Date:
June 24, 2022
Export Citation:
Assignee:
NATIONAL UNIV CORPORATION OITA UNIV (JP)
International Classes:
C07D413/04; A61K31/4245; A61K31/454; A61P31/12; C07D413/14
Domestic Patent References:
| WO2018051254A1 | 2018-03-22 | |||
| WO2018051255A1 | 2018-03-22 | |||
| WO2016001820A1 | 2016-01-07 | |||
| WO2015198263A2 | 2015-12-30 | |||
| WO2014105926A1 | 2014-07-03 | |||
| WO2020067930A1 | 2020-04-02 | |||
| WO2021201036A1 | 2021-10-07 |
Foreign References:
| JP2013522375A | 2013-06-13 | |||
| JP2013515746A | 2013-05-09 | |||
| JP2008501752A | 2008-01-24 | |||
| JP2006523669A | 2006-10-19 | |||
| JP2004500355A | 2004-01-08 | |||
| JP2004123556A | 2004-04-22 | |||
| JP2004123557A | 2004-04-22 | |||
| JP2004502688A | 2004-01-29 | |||
| JP2009526065A | 2009-07-16 | |||
| JP2002516904A | 2002-06-11 | |||
| JP2016504284A | 2016-02-12 | |||
| JP2017537118A | 2017-12-14 | |||
| JP2015506348A | 2015-03-02 | |||
| JP2021106034A | 2021-07-26 |
Other References:
KANG IOU-JIUN, HSU SHENG-JU, YANG HUI-YUN, YEH TENG-KUANG, LEE CHUNG-CHI, LEE YEN-CHUN, TIAN YA-WEN, SONG JEN-SHIN, HSU TSU-AN, CH: "A Potent, Selective, and Orally Bioavailable HCV NS5A Inhibitor for Treatment of Hepatitis C Virus: ( S )-1-(( R )-2-(Cyclopropanecarboxamido)-2-phenylacetyl)- N -(4-phenylthiazol-2-yl)pyrrolidine-2-carboxamide", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 60, no. 1, 12 January 2017 (2017-01-12), US , pages 228 - 247, XP093016829, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.6b00962
BARR, R.GREEN, C. A.SANDE, C. J.DRYSDALE, S. B., THER. ADV. INFECTIOUS DIS., vol. 6, 2019, pages 1 - 9
DOMACHOWSKE, J. B.ANDERSON, E. J.GOLDSTEIN, M.: "The Future of Respiratory Syncytial Virus Disease Prevention and Treatment", INFECT. DIS. THER., vol. 10, 2021
ALJABR, W.TOUZELET, 0.POLLAKIS, G.WU, W.MUNDAY, D. C.HUGHES, M.HERTZ-FOWLER, C.KENNY, J.FEARNS, R.BARR, J. N.: "Investigating the Influence of Ribavirin on Human Respiratory Syncytial Virus RNA Synthesis by Using a High-Resolution Transcriptome Sequencing Approach", J. VIROL., vol. 90, 2015, pages 4876 - 4888
HIROYUKI TSUTSUMI, CLINICAL SIGNIFICANCE OF PALIVIZUMAB ADMINISTRATION, INFECTIOUS AGENTS SURVEILLANCE REPORT (IASR, vol. 39, 2018, pages 219 - 220
K. OKADAM. MIZUNOH. MORIUCHI, SKUSUDA, IMORIOKA, Y.MORI, K.OKAMOTO, K.OKADA, S.YOSHIHARA, T.YAMAGISHI, U.: "Japanese Journal of Pediatrics", vol. 123, 2019, JAPANESE SOCIETY OF PAEDIATRICS COMMITTEE, article "Consensus Guidelines for the Use of Palivizumab in Japan", pages: 807 - 813
PETER G. M. WUTS: "Greene's Protecting groups in Organic Synthesis", 2014, JOHN WILEY & SONS, INC.
HARRISON ET AL.: "Compendium of Synthetic Organic Methods", vol. 1-8, 2015, JOHN WILEY & SONS
RC. LAROCK: "Comprehensive Organic Transformations", 1999, JOHN WILEY AND SONS, INC.
BARR, R.GREEN, C. A.SANDE, C. J.DRYSDALE, S. B., THER. ADV. INFECTIOUS DIS., vol. 6, 2019, pages 1 - 9
DOMACHOWSKE, J. B.ANDERSON, E. J.GOLDSTEIN, M.: "The Future of Respiratory Syncytial Virus Disease Prevention and Treatment", INFECT. DIS. THER., vol. 10, 2021
ALJABR, W.TOUZELET, 0.POLLAKIS, G.WU, W.MUNDAY, D. C.HUGHES, M.HERTZ-FOWLER, C.KENNY, J.FEARNS, R.BARR, J. N.: "Investigating the Influence of Ribavirin on Human Respiratory Syncytial Virus RNA Synthesis by Using a High-Resolution Transcriptome Sequencing Approach", J. VIROL., vol. 90, 2015, pages 4876 - 4888
HIROYUKI TSUTSUMI, CLINICAL SIGNIFICANCE OF PALIVIZUMAB ADMINISTRATION, INFECTIOUS AGENTS SURVEILLANCE REPORT (IASR, vol. 39, 2018, pages 219 - 220
K. OKADAM. MIZUNOH. MORIUCHI, SKUSUDA, IMORIOKA, Y.MORI, K.OKAMOTO, K.OKADA, S.YOSHIHARA, T.YAMAGISHI, U.: "Japanese Journal of Pediatrics", vol. 123, 2019, JAPANESE SOCIETY OF PAEDIATRICS COMMITTEE, article "Consensus Guidelines for the Use of Palivizumab in Japan", pages: 807 - 813
PETER G. M. WUTS: "Greene's Protecting groups in Organic Synthesis", 2014, JOHN WILEY & SONS, INC.
HARRISON ET AL.: "Compendium of Synthetic Organic Methods", vol. 1-8, 2015, JOHN WILEY & SONS
RC. LAROCK: "Comprehensive Organic Transformations", 1999, JOHN WILEY AND SONS, INC.
Attorney, Agent or Firm:
YAMAO, Norihito et al. (JP)
Download PDF: